TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:00
NEKTAR THERAPEUTICS ( NKTR ) https://www.nektar.com
0.90USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
NKTR
26.76%
SPY
32.74%
-95.50%
NKTR
SPY
92.93%
-97.32%
NKTR
SPY
224.41%
-92.35%
NKTR
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
171.73
-18.23
1.47
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.58
1.95
1.31
-171.59
0.00
0.15
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-185.82
48.51
-131.33
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.5222
-105.29
-36.28
1.14
Other Earnings and Cash Flow Stats:
NEKTAR THERAPEUTICS ( NKTR ) Net Income TTM ($MM) is -301.59
NEKTAR THERAPEUTICS ( NKTR ) Operating Income TTM ($MM) is -160.24
NEKTAR THERAPEUTICS ( NKTR ) Owners' Earnings Annual ($MM) is -270.58
NEKTAR THERAPEUTICS ( NKTR ) Current Price to Owners' Earnings ratio is -0.64
NEKTAR THERAPEUTICS ( NKTR ) EBITDA TTM ($MM) is -131.21
NEKTAR THERAPEUTICS ( NKTR ) EBITDA Margin is -131.33%
Capital Allocation:
NEKTAR THERAPEUTICS ( NKTR ) has paid 0.00 dividends per share and bought back -4.246 million shares in the past 12 months
NEKTAR THERAPEUTICS ( NKTR ) has reduced its debt by 13.72 million USD in the last 12 months
Capital Structure:
NEKTAR THERAPEUTICS ( NKTR ) Interest-bearing Debt ($MM) as of last quarter is 117
NEKTAR THERAPEUTICS ( NKTR ) Annual Working Capital Investments ($MM) are 7
NEKTAR THERAPEUTICS ( NKTR ) Book Value ($MM) as of last quarter is 130
NEKTAR THERAPEUTICS ( NKTR ) Debt/Capital as of last quarter is 89%
Other Balance Sheet Stats:
NEKTAR THERAPEUTICS ( NKTR ) has 35 million in cash on hand as of last quarter
NEKTAR THERAPEUTICS ( NKTR ) has 51 million of liabilities due within 12 months, and long term debt 0 as of last quarter
NEKTAR THERAPEUTICS ( NKTR ) has 191 common shares outstanding as of last quarter
NEKTAR THERAPEUTICS ( NKTR ) has 0 million USD of preferred stock value
Academic Scores:
NEKTAR THERAPEUTICS ( NKTR ) Altman Z-Score is -12.25 as of last quarter
NEKTAR THERAPEUTICS ( NKTR ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
NEKTAR THERAPEUTICS ( NKTR ) largest shareholder is owning shares at 0.00 ($MM) value
Jonathan Zalevsky(an insider) Sold 9014 shares of NEKTAR THERAPEUTICS ( NKTR ) for the amount of $6129.52 on 2024-02-20
1.07% of NEKTAR THERAPEUTICS ( NKTR ) is held by insiders, and 97.38% is held by institutions
NEKTAR THERAPEUTICS ( NKTR ) went public on 1994-05-03
Other NEKTAR THERAPEUTICS ( NKTR ) financial metrics:
FCF:-239.63
Unlevered Free Cash Flow:-178.68
EPS:-0.96
Operating Margin:-185.82
Gross Profit Margin:48.51
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-139.97
Beta:1.14
Buffet's Owners Earnings:-270.58
Price to Owner's Earnings:-0.64
About NEKTAR THERAPEUTICS ( NKTR ) :
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.